TEVA ▼ -0.5% - Teva Pharmaceutical Industries Limited $TEVA - Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults Teva Pharmaceutical fell 0.5% today following the announcement of post hoc data for its experimental olanzapine long-acting injectable (TEV-749), which demonstrated high stabilization rates and sustained efficacy in schizophrenia patients when dosed once monthly via subcutaneous injection. The modest decline suggests investors may be waiting for additional catalysts or phase progression updates before assigning meaningful value to the candidate, despite the positive efficacy signals in the data presented. 18-SEP-2026 04:30 PM ET